Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Gilead Wagers $275m On Pionyr’s Myeloid Tuners

Executive Summary

Deal snapshot: Pionyr’s top two candidates are preclinical, but Gilead buys near 50% stake in the hope that myeloid tuners will work in combination with anti-PD-L1 agents in solid tumors.

You may also be interested in...



Finance Watch: Arbor, Acrivon, Bit.Bio Close VC Mega-Rounds

Private Company Edition: Arbor is developing drugs based on proprietary gene editors, Acrivon is applying proteomics to precision cancer therapies, and bit.bio is producing differentiated cell products. Also, Marengo launches with $80m, Sanofi invests up to $60m in Gyroscope and Shasqi raises $50m.

Gilead Buys Pipeline-In-A-Product With $21bn Immunomedics Deal

The company paid twice Immunomedics’ last closing stock price to access Trodelvy, approved for triple-negative breast cancer with potential in other solid tumors as monotherapy and in combinations.

Gilead Gets Option To Tizona's Novel HLA-G Checkpoint, Further Bulking Up Immune Checkpoint Arsenal

The big biotech will pay $300m to acquire a 49.9% equity interest in the cancer immunotherapy startup with a buyout option. It is one of several immune checkpoints Gilead has secured access to this year.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

SC142457

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel